Valeant Pharmaceuticals Intl Inc VRX shares are trading higher by $0.90 (6 percent) at $15.86 in Tuesday's session.
The Street has taken a liking to the company after it was announced Monday afternoon it struck a litigation deal with Pershing Square regarding potential costs among the parties in the event of a settlement from pending legal disputes.
The issue also seemed to move in sympathy after StreetInsider reported of takeover chatter in Bristol-Myers Squibb Co BMY.
After a higher open, it retreated and found support one penny under Monday's close ($14.97), reaching $14.96 before continuing its move higher.
So far, the ensuing rally has taken the issue to $15.99. That marks the highest level for the issue since it peaked on January 11 at $16.69, but faltered to close at $15.33.
It hasn't closed above $16.00 since January 10, when it ended that session at $16.40.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
